ArticlePatient preference and adherence2025

Clinicians' Perspectives of Twice-Weekly Rivastigmine Patches for Alzheimer's Disease Treatment in Spain: The VIITAL 2S Study.

Gerard Piñol-Ripoll et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.